Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial.
OBJECTIVE
To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case-control study nested in the Prostate Cancer Prevention Trial (PCPT).


METHODS
Cases were men with a confirmed diagnosis of PCa after visit 2 (n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy (n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies.


RESULTS
No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89-1.45).


CONCLUSIONS
Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.
Division of Public Health Sciences and the Alvin J. Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, 660 S. Euclid Ave., Rm. 5026, Box 8100, St. Louis, MO 63110, USA. sutcliffes@wudosis.wustl.edu
Siobhan
S
Sutcliffe
Cathee
C
Till
Charlotte A
CA
Gaydos
Frank J
FJ
Jenkins
Phyllis J
PJ
Goodman
Ashraful M
AM
Hoque
Ann W
AW
Hsing
Ian M
IM
Thompson
Jonathan M
JM
Zenilman
William G
WG
Nelson
Angelo M
AM
De Marzo
Elizabeth A
EA
Platz
D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003587:Cytomegalovirus / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000097:blood / Q000150:complications / Q000453:epidemiology* / Q000382:microbiology; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control; D012307:Risk Factors; D016036:Seroepidemiologic Studies
D058891:5-alpha Reductase Inhibitors; D018120:Finasteride